Correction to: A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (International Journal of Hematology, (2019), 109, 1, (107-114), 10.1007/s12185-018-2543-y)

on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

Research output: Contribution to journalComment/debate

Abstract

In the original publication of this article, “Conflict of interest” was published incorrectly. The corrected “Conflict of interest” is given below for your reading. Conflict of interest Dr. Sunami reports grants from GlaxoSmithKline, Novartis, Janssen, Sanofi, MSD, Alexion Pharma, Daiichi-Sankyo, and Abbvie, and grants and personal fees from Ono pharmaceutical, Takeda pharmaceutical, Celgene, and Bristol-Myers Squibb. Dr. Matsumoto reports personal fees from Celgene, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda Pharmaceutical. Dr. Okumura reports personal fees from Celgene. Dr. Murayama reports personal fees from Bristol-Myers Squibb, Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Janssen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.

Original languageEnglish
Number of pages1
JournalInternational journal of hematology
Volume109
Issue number1
DOIs
Publication statusPublished - Jan 22 2019

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this